• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.net
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Wealth Creation

VASRO GmbH > Press > Wealth Creation
VASRO GmbH

Charles River Laboratories Experiences Significant Stock Surge

  • May 20, 2025
  • Pharma & Biotech
Charles River Laboratories' stock surge reflects strong financial results, governance changes, and strategic growth initiatives, boosting investor confidence.
Continue Reading
VASRO GmbH

Top 10 Equity Analysis Techniques Used by Leading Research Firms

  • May 19, 2025
  • Unkategorisiert
Discover the top 10 equity analysis techniques used by leading research firms to evaluate stocks, mitigate risks, and optimize investment strategies.
Continue Reading
VASRO GmbH

Energy Innovations Driving Strategic Industry Trends in 2025

  • May 15, 2025
  • Energy
Energy innovations in 2025 are driving industry trends, boosting sustainability, efficiency, and growth through renewables, storage, and green hydrogen.
Continue Reading
VASRO GmbH

Top European Dividend Stocks to Watch for Maximum Returns in 2025

  • May 8, 2025
  • Energy, Commodity, Real Estate, Pharma & Biotech, Tech
Discover top European dividend stocks to watch in 2025, including undervalued gems offering high yields and stability for income-focused investors.
Continue Reading
VASRO GmbH

What Are the Sustainability Challenges of AI’s Energy Consumption

  • May 5, 2025
  • Energy, Tech
AI's energy hunger reshapes equity analysis in the energy sector, straining resources, increasing emissions, and challenging sustainability goals globally.
Continue Reading
VASRO GmbH

5 Top Pharma Stocks to Watch for Strong Growth in 2025

  • May 2, 2025
  • Pharma & Biotech
Discover the 5 top pharma stocks to watch in 2025. Gain equity analysis insights on Eli Lilly, J&J, Merck, Thermo-Fisher, and AbbVie for strong growth.
Continue Reading
VASRO GmbH

J&J unveils promising durability data for bladder cancer ‘pretzel’ drug

  • May 1, 2025
  • Pharma & Biotech
J&J reports durability data for bladder cancer 'pretzel' drug TAR-200, showing a 72.7% complete response rate and sustained benefits after FDA filing.
Continue Reading
VASRO GmbH

Key Trends Shaping Renewable Energy in the Tech Industry

  • April 30, 2025
  • Energy, Tech
The rise of green energy: how renewable energy is transforming the tech industry in 2025 through AI, data centers, and innovative energy solutions.
Continue Reading
VASRO GmbH

The Rise of Green Pharma: How Renewable Energy is Transforming the Pharmaceutical Industry

  • April 29, 2025
  • Energy, Pharma & Biotech
Green Pharma is revolutionizing the pharmaceutical industry by using renewable energy to cut emissions, reduce waste, and promote sustainable drug manufacturing.
Continue Reading

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY September 7, 2026
Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY August 31, 2026
Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update August 12, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • Info@vasro.net
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.